<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-058097</identifier>
<setSpec>0300-8932</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Metalloproteases, vascular remodeling and atherothrombotic syndromes</dc:title>
<dc:description xml:lang="en">Defects in the synthesis and breakdown of the extracellular matrix (ECM) are now seen as key processes in the development of atherosclerosis and its thrombotic complications. Correlations have been observed between circulating levels of ECM biomarkers and the clinical manifestations of and risk factors for atherosclerosis. Several matrix metalloproteinases (MMPs), endopeptidases that can degrade the ECM, such as MMP-9 and MMP-10, play important roles in the pathophysiology of atherothrombosis and contribute to the expansion of abdominal aortic aneurysms. Moreover, they may also be useful biomarkers of atherosclerotic risk and serve as predictors of coronary and cerebrovascular disease recurrence. Although at present the effect of tissue inhibitors of MMPs (TIMPs) on cardiovascular disease prognosis is still uncertain, the ECM could be a promising therapeutic target in atherothrombotic disease, and several MMP inhibitors are currently undergoing clinical trials Defects in the synthesis and breakdown of the extracellular matrix (ECM) are now seen as key processes in the development of atherosclerosis and its thrombotic complications. Correlations have been observed between circulating levels of ECM biomarkers and the clinical manifestations of and risk factors for atherosclerosis. Several matrix metalloproteinases (MMPs), endopeptidases that can degrade the ECM, such as MMP-9 and MMP-10, play important roles in the pathophysiology of atherothrombosis and contribute to the expansion of abdominal aortic aneurysms. Moreover, they may also be useful biomarkers of atherosclerotic risk and serve as predictors of coronary and cerebrovascular disease recurrence. Although at present the effect of tissue inhibitors of MMPs (TIMPs) on cardiovascular disease prognosis is still uncertain, the ECM could be a promising therapeutic target in atherothrombotic disease, and several MMP inhibitors are currently undergoing clinical trials (AU)</dc:description>
<dc:creator>Páramo, José A</dc:creator>
<dc:creator>Orbe, Josune</dc:creator>
<dc:creator>Rodríguez, José A</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Las alteraciones en la síntesis y/o la degradación de la matriz extracelular (MEC) emergen como procesos clave en el desarrollo de la aterosclerosis y sus complicaciones trombóticas. Se ha observado una asociación entre los biomarcadores circulantes de la MEC y las manifestaciones clínicas y los factores de riesgo ateroscleróticos. Diversas metaloproteasas (MMP), endopeptidasas que degradan la MEC, como MMP-9 y 10, además de desempeñar un papel relevante en la fisiopatología del proceso aterotrombótico y contribuir a la expansión de los aneurismas arteriales, pueden ser de utilidad como biomarcadores de riesgo aterosclerótico y predictores de recurrencia de enfermedad coronaria y cerebrovascular. Aunque actualmente el papel de los inhibidores de MMP (TIMP) en el pronóstico cardiovascular es más incierto, la MEC puede representar una diana terapéutica atractiva en la aterotrombosis, y diversos inhibidores de las MMP se encuentran en fase de investigación clínica (AU)</dc:description>
<dc:source>Rev Esp Cardiol;60(9): 959-967, sept. 2007. ilus, tab</dc:source>
<dc:identifier>ibc-058097</dc:identifier>
<dc:title xml:lang="es">Metaloproteasas, remodelado vascular y síndromes aterotrombóticos</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d23568^s22002</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d5208^s22031</dc:subject>
<dc:subject>^d7152^s22012</dc:subject>
<dc:subject>^d9951^s22012</dc:subject>
<dc:subject>^d31490^s22032</dc:subject>
<dc:subject>^d7130^s22012</dc:subject>
<dc:subject>^d1166^s22032</dc:subject>
<dc:subject>^d38178^s22006</dc:subject>
<dc:subject>^d36032^s22012</dc:subject>
<dc:subject>^d3942^s22012</dc:subject>
<dc:subject>^d38178^s22002</dc:subject>
<dc:type>article</dc:type>
<dc:date>200709</dc:date>
</metadata>
</record>
</ibecs-document>
